Quality of life study for adults with CLL or SLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL
- You are about to start treatment with a BTK inhibitor (like ibrutinib or acalabrutinib) with or without an anti-CD20 antibody, or a BCL2 inhibitor (like venetoclax) with obinutuzumab.
- You can read and speak English or Spanish at an 8th grade level.
- You do not have dementia, traumatic brain injury, or leukemia that has spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This study tests a new oral medication called pirtobrutinib in people with previously untreated CLL or SLL. Researchers will collect blood and lymph node samples to understand how the immune system responds to the drug.
This study looks at real-world experiences of people with chronic lymphocytic leukemia (CLL) who have used or are using a type of targeted therapy called a BCL-2 inhibitor. It aims to understand how well these treatments work and their side effects in everyday practice.
This study looks at quality of life in people age 70 and older with slow-growing (low-grade) B-cell non-Hodgkin lymphoma who haven’t been treated yet. It requires a geriatric (aging-focused) check before starting care, to see what helps older patients feel better during treatment.
This study looks at what happens to patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after they stop taking a type of targeted therapy called a BTK inhibitor. It aims to understand treatment patterns and outcomes to help guide future care.
Hear when a new Small Lymphocytic Lymphoma (SLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.